Anti-drug antibodies


Submitted: 13 March 2012
Accepted: 31 May 2012
Published: 21 September 2012
Abstract Views: 6884
PDF: 2054
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

  • Clemens Warnke Karolinska Institutet, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden; Department of Neurology, Medical Faculty, Heinrich-Heine-University Düsseldorf, Germany, Sweden.
  • Christina Hermanrud Karolinska Institutet, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden.
  • Malin Lundkvist Karolinska Institutet, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska University Hospital, Stockholm, Sweden, Sweden.
  • Anna Fogdell-Hahn Karolinska Institutet, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska University Hospital Stockholm, Sweden.
Biological pharmaceuticals are increasingly used in modern medicine and give remarkable improvements for many different patient groups. Unfortunately, for several of these compounds, undesirable immune reactions are induced against the drug. The resulting anti-drug antibodies modify the pharmacokinetic and pharmacodynamic properties of the drug and, by blocking the drug-target interaction, reduce the effects of the treatment. Anti-drug antibodies may also increase the risk of hypersensitivity reactions by the formation of immune complexes. Furthermore, by cross-reacting with the endogenous homolog of the drug, the anti-drug antibodies might impair important physiological functions even after treatment cessation. As a consequence, anti-drug antibodies need to be taken in account when estimating the benefit-burden ratio of a treatment for an individual patient, but also when calculating the value of therapeutics on a socio-economic level. In this review we give an overview over the current understanding of the immunogenicity against drugs, exemplified for patients with hemophilia A, multiple sclerosis, rheumatoid arthritis and Crohn’s disease. We discuss known and potential risk factors for anti-drug antibody formation and finally outline suggested strategies for prediction and prevention.

Supporting Agencies

ECTRIMS

Warnke, C., Hermanrud, C., Lundkvist, M., & Fogdell-Hahn, A. (2012). Anti-drug antibodies. Drugs and Therapy Studies, 2(1), e11. https://doi.org/10.4081/dts.2012.e11

Downloads

Download data is not yet available.

Citations